ClinicalTrials.gg
Not yet recruitingNCT07650942Updated Jun 16, 2026

Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis

A Phase 3 interventional study of Hemay005 tablet and Placebo in Ulcerative Colitis (UC), sponsored by Ganzhou Hemay Pharmaceutical Co., Ltd. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Ganzhou Hemay Pharmaceutical Co., Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 183 studies in Colitis, Ulcerative with a site in China — 72 open to participants now, 95 under way, 25 of them phase 3. Colitis, Ulcerative · China.

Planned enrollment
29th of 135
360 · median 120
Started
2026
with 27 others
Phase 3
32 of 183
9 open now
Primary completion
2028-05
later than 67 of 94 live
Registered
170th of 183
by date

Among the 183 studies in Colitis, Ulcerative with a site in China, this one is the 29th largest by planned enrollment of the 135 interventional ones that give a count, is one of 28 that started in 2026, is one of 32 in phase 3, reaches primary completion later than 67 of the 94 other live ones, and was the 170th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

72 of the 183 studies in Colitis, Ulcerative with a site in China are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 183 studies in Colitis, Ulcerative with a site in China, or all of them as a file.
02

Study summary

The purpose of this phase III, multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of Hemay005 compared to placebo as induction and maintenance therapy in Chinese participants with moderately to severely active ulcerative colitis.

Read the detailed description

This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety of Hemay005 in induction and maintenance therapy in Chinese patients with moderately or severely active ulcerative colitis. The study consists of two independent phases: an 12-week Induction Phase (might including an 12-week Extended Induction phase, depending on the participant status by the end of the induction treatment) and a 40-week Maintenance Phase. Screening period will be up to 5 Weeks.

In the Induction Phase, participants will be randomized 2:1 to receive either Hemay005 (twice daily) or placebo for 12 weeks. The randomization will be stratified by: exposed to advanced therapy (yes/no); disease severity (modified Mayo score of 5-6 or 7-9) and baseline corticosteroid use (yes/no). Participants who have not show clinical response (either receive Hemay005 or placebo) by week 12 will undergo an extended 12-week induction treatment with Hemay005.

After completing the Induction Phase (or the Extended Induction Phase), participants with response are eligible to go to the Maintenance Phase. Participants with a response to Hemay005 by week 12 of the Induction Phase and those with a response by the end of the Extended Induction Phase) will be randomized 1:1 to receive either Hemay005 (twice daily) or placebo for 40 weeks. Randomization will be stratified by corticosteroid use at the start date of Maintenance Phase (yes/no) and clinical remission status by the end of Induction Phase (yes/no). Participants who are assigned to placebo during the Induction Phase and have demonstrated a clinical response will continue to receive blinded placebo during the Maintenance Phase. Participants who have not showed a clinical response by week 12 of the Induction Phase but have a response to Hemay005 by the end of the Extended Induction Phase will continue to receive blinded Hemay005 during the Maintenance Phase.

During the Maintenance Phase, participants who are demonstrated loss of response will be eligible to go to the open-label treatment phase and treated with Hemay005. The total duration of open-label treatment phase will not exceed 40 weeks since the participant enrolled into the Maintenance Phase.

03

Conditions studied

  • Ulcerative Colitis (UC)

Keywords

  • Inflammatory Bowel Disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women 18 to 80 years of age, inclusive, at the time of consent.
  2. Voluntarily to give written .
  3. Diagnosed with UC established at least 3 months prior to screen visit. The diagnosis must be confirmed by clinical and endoscopic evidence, corroborated by a histopathology report.
  4. Active UC confirmed by endoscopy, classified as Montreal E2 or E3.
  5. Moderately to severely active UC, defined as mMS of 5 to 9 points, including a MES of at least 2 (confirmed through centrally read endoscopy) and a SFS of at least 1 and a RBS of at least 1. The endoscopy should be performed within 14 days prior to randomization.
  6. Demonstrated inadequate response, loss of response and/or intolerance to at least one of the following UC therapies:

    A) Conventional therapies, including oral 5-aminosalicylic acid (5-ASA) compounds, , immunoregulatory agents.

    B) Advanced therapies: biologics (including but not limit to antitumor necrosis factor alpha (TNFα) antibodies, anti-integrin antibodies, anti-interleukin 12/23 antibodies) and small molecule therapies(including but not limit to JAK inhibitors, S1P receptor modulators) Note: The medication used to qualify the subject for entry into this category must be approved for the treatment of UC in the country of use and the subject must have received an adequate course of therapy based on local guidelines for that therapy.

  7. For female participants of : agreement to remain abstinent (refrain from heterosexual intercourse) or use adequate and agreement to refrain from egg donation or undergo fertility treatment during the treatment period and for 30 days after the final dose of Hemay005. For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agree to refrain from donating sperm during the treatment period and for 30 days after the final dose of Hemay005.

Exclusion criteria

Exclusion Criteria:

  1. Current diagnosis of CD, abdominal/intrabdominal/perianal fistula and/or abscess, indeterminant colitis, IBD-unclassified, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, or active diverticular disease.
  2. Severe UC as evidenced by any of the following:

    A) Hospitalization for the treatment of UC ≤ 2 weeks prior to screening or, in the physician's judgement, is likely to require hospitalization for medical care or surgical intervention of any kind for UC during the study.

    B)Current evidence of fulminant colitis, toxic megacolon, or recent history (within 6 months) of toxic megacolon, or bowel perforation.

    C)Prior history of subtotal, or total colectomy.

  3. Past or current evidence of any gastrointestinal , either prior to or at the time of screening. History of malignancy within 5 years prior to screening visit, with the exception of malignancies adequately treated with resection for non- basal cell or squamous cell cancer or in situ cervical cancer.
  4. Past or current evidence of definite low-grade or high-grade colonic dysplasia or adenomas or neoplasia not completely removed.
  5. Significant uncontrolled medical comorbidity (such as cardiac, pulmonary, renal, hepatic, endocrine, ), psychiatric, or other condition that in the opinion of the investigator, would confound the study results, compromise patient safety, interfere with the potential participant's provision of , or compliance with trial procedures.
  6. Evidence of infection with Clostridioides difficile (C. difficile; formerly known as Clostridium difficile), cytomegalovirus (CMV), (HIV), (HBV), (HCV).
  7. Evidence of active tuberculosis (TB).
  8. Any condition that would preclude endoscopic evaluation.
  9. Either received protocol-specified prohibited medicines prior to baseline endoscopy and/ or randomization, or have not be washed out sufficiently due to the protocol before baseline endoscopy and/ or randomization.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Induction Treatment Arm

    60mg, administratered orally, twice daily

    Drug: Hemay005 tablet

  • Placebo comparator
    Induction Comparator Arm

    matching tablet, administratered orally, twice daily

    Drug: Placebo

  • Experimental
    Maintenance Treatment Arm

    60mg, administratered orally, twice daily

    Drug: Hemay005 tablet

  • Placebo comparator
    Maintenance Comparator Arm

    matching tablet, administratered orally, twice daily

    Drug: Placebo

Interventions

  • Participants receive treatment with Hemay005 tablet during the Induction Phase (week I-0\~I-12).

  • DrugPlacebo

    Participants receive treatment with placebo tablet during the Induction Phase (week I-0\~I-12).

  • Participants receive treatment with Hemay005 tablet during the Maintenance Phase (week M-0\~M-40).

  • DrugPlacebo

    Participants receive treatment with placebo during the Maintenance Phase (week M-0\~M-40).

06

What researchers measure

Primary outcomes

  1. Induction Phase: Percentage of Participants With Clinical Remission at Week 12.

    Clinical remission is based on the Modified Mayo Score (mMS). The Modified Mayo Score (mMS) consists of Rectal Bleeding Subscore (RBS), Stool Frequency Subscore (SFS) and Mayo Endoscopic Subscore (MES). Each subscore ranges from 0 to 3 and a total mMS ranging from 0 to 9, with higher scores indicating more severe disease. Clinical remission is defined as a SFS of 0 or 1 with a decrease of at least 1 from baseline , and a RBS of 0, and a MES of 0 or 1 without friability.

    Time frame: Induction Phase Week 12

  2. Maintenance Phase: Percentage of Participants With Clinical Remission at Week 40.

    Clinical remission is defined as a SFS of 0 or 1 with a decrease of at least 1 from baseline , and a RBS of 0, and a MES of 0 or 1 without friability.

    Time frame: Maintenance Phase: Week 40

Secondary outcomes

  1. Induction Phase: Percentage of Participants With Endoscopic Improvement at Week 12.

    Endoscopic Improvement is based on the Mayo Endoscopic Subscore (MES). The MES ranges from 0 to 3, with higher scores indicating more severe disease. Endoscopic Improvement is defined as MES of 0 or 1(without friability).

    Time frame: Induction Phase: At Week 12

  2. Induction Phase: Percentage of Participants With Completely Symptomatic Remission at Week 12.

    Complete Symptomatic Remission is defined as a SFS of 0 and a RBS of 0.

    Time frame: At Week 12

  3. Induction Phase: Percentage of Participants With Symptomatic Remission at Week 12.

    Symptomatic Remission is defined as a SFS of 0 or 1 with a decrease of at least 1 from baseline and a RBS of 0.

    Time frame: At Week 12

  4. Induction Phase: Percentage of Participants With Clinical Response at Week 12.

    Clinical response is based on the Modified Mayo Score (mMS). The Modified Mayo Score (mMS) consists of Rectal Bleeding Subscore (RBS), Stool Frequency Subscore (SFS) and Mayo Endoscopic Subscore (MES). Each subscore ranges from 0 to 3 and a total mMS ranging from 0 to 9, with higher scores indicating more severe disease. Clinical Response is defined as a decrease in mMS of at least 2 points and 30% from baseline and either a decrease of at least 1 in RBS or a RBS of 0 or 1.

    Time frame: At Week 12

  5. Induction Phase: Percentage of Participants With Endoscopic Response at Week 12.

    Endoscopic Response is defined as a decrease of at least 1 in MES from baseline.

    Time frame: At Week 12

  6. Induction Phase: Percentage of Participants With Symptomatic Response at Week 12.

    Symptomatic Response is defined as a a decrease of ≥30% in the sum of RBS and SFS from baseline.

    Time frame: At Week 12

  7. Maintenance Phase: Percentage of Participants With Endoscopic Improvement at Week 40.

    Endoscopic Improvement is defined as MES of 0 or 1 (without friability).

    Time frame: At Week 40

  8. Maintenance Phase: Percentage of Participants with a Clinical Remission both at Week 12 of Induction Phase and Week 40 of Maintenance Phase.

    Clinical remission is defined as a SFS of 0 or 1 with a decrease of at least 1 from baseline , and a RBS of 0, and a MES of 0 or 1 without friability.

    Time frame: At Week 40

  9. Maintenance Phase: Percentage of Participants With Steroid-free Clinical Remission at Week 40.

    Steroid-free Clinical Remission is defined as achieving clinical remission and have not used corticosteroids to treat UC for at least 8 weeks.

    Time frame: At Week 40

  10. Maintenance Phase: Percentage of Participants With Endoscopic Response at Week 40.

    Endoscopic Response is defined as a decrease of at least 1 in MES from baseline.

    Time frame: At Week 40

  11. Maintenance Phase: Percentage of Participants with a Clinical Response both at Week 12 of Induction Phase and Week 40 of Maintenance Phase.

    Clinical Response is defined as a decrease in mMS of at least 2 points and 30% from baseline and either a decrease of at least 1 in RBS or a RBS of 0 or 1.

    Time frame: At Week 40

  12. Maintenance Phase: Percentage of Participants With Complete Symptomatic Remission.

    Complete Symptomatic Remission is defined as a SFS of 0 and a RBS of 0.

    Time frame: Maintenance Phase: At Week 8, Week 16, Week 24, Week 32, Week 40.

  13. Maintenance Phase: Percentage of Participants With Symptomatic Remission.

    Symptomatic Remission is defined as a SFS of 0 or 1 with a decrease of at least 1 from baseline and a RBS of 0.

    Time frame: Maintenance Phase: At Week 8, Week 16, Week 24, Week 32, Week 40.

  14. Maintenance Phase:Percentage of Participants With Symptomatic Response.

    Symptomatic Response is defined as a a decrease of ≥30% in the sum of RBS and SFS from baseline.

    Time frame: Maintenance Phase: At Week 8, Week 16, Week 24, Week 32, Week 40.

Other outcomes

  1. Change of calprotectin from baseline.

    Time frame: At Week 12 of Induction Phase and Week 40 of Maintenance Phase.

  2. Among participants with abnormal calprotectin at baseline, percentage of participant with normalized calprotectin.

    Time frame: At Week 12 of Induction Phase and Week 40 of Maintenance Phase.

  3. Change of modified Mayo score from baseline.

    The Modified Mayo Score (mMS) consists of Rectal Bleeding Subscore (RBS), Stool Frequency Subscore (SFS) and Mayo Endoscopic Subscore (MES). Each subscore ranges from 0 to 3 and a total mMS ranging from 0 to 9, with higher scores indicating more severe disease.

    Time frame: At Week 12 of Induction Phase and at Week 40 of Maintenance Phase.

  4. Change of partial modified Mayo score from baseline.

    The partial modified Mayo Score (pmMS) consists of Rectal Bleeding Subscore (RBS) and Stool Frequency Subscore (SFS). Both RBS and SFS range from 0 to 3, with higher scores indicating more severe disease.

    Time frame: Induction Phase: At Week 2, Week 4, Week 8, Week 12. Maintenance Phase: At Week 8, Week 16, Week 24, Week 32, Week 40.

  5. Change of IBDQ score from baseline.

    The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with ulcerative colitis. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.

    Time frame: At Week 12 of Induction Phase and at Week 40 of Maintenance Phase.

  6. Among participants with abnormal C-reactive protein at baseline, percentage of participant with normalized C-reactive protein.

    Time frame: At Week 12 of Induction Phase and at Week 40 of Maintenance Phase.

  7. Incidence and Severity of Adverse Events, Serious Adverse Events, Adverse Events Leading to Discontinuation, Adverse events of Special Interest.

    Time frame: From Week 0 of Induction Phase to Week 40 of Maintenance Phase

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for May 2028, 23 months later.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's planned 23 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2026
First posted
Jun 16, 2026
StartEst.
Jun 2026
Primary completionEst.
May 2028
CompletionEst.
Feb 2029
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07650942
Lead sponsor
Ganzhou Hemay Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Jun 16, 2026
Start date
Jun 2026 (estimated)
Primary completion
May 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
Jun 16, 2026

Study contacts

Han Hai
Contact
haihan@hemay.com.cn
86-22-24929530
Minhu Chen, M.D
principal investigator · First Affiliated Hospital, Sun Yat-Sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hemay005

Start the discussion